Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 1/20 | 0.42 |
| ▸ | GALR2 | O43603 | 3/20 | 0.42 |
| ▸ | GALR1 | P47211 | 3/20 | 0.42 |
| ▸ | IDH2 | P48735 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 3/20 | 0.40 |
| ▸ | CTSS | P25774 | 3/20 | 0.40 |
| ▸ | CTSK | P43235 | 3/20 | 0.40 |
| ▸ | CTSB | P07858 | 2/20 | 0.40 |
| ▸ | CTSV | O60911 | 1/20 | 0.39 |
| ▸ | PLAT | P00750 | 1/20 | 0.39 |
| ▸ | CTSH | P09668 | 1/20 | 0.39 |
| ▸ | CASP14 | P31944 | 1/20 | 0.39 |
| ▸ | CASP6 | P55212 | 1/20 | 0.39 |
| ▸ | CTSZ | Q9UBR2 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 2/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4832751 | 0.90 | GALR2 (0.54) | GALR2GALR1CTSLCTSSCTSK | |
| SCHEMBL4841107 | 0.86 | CTSL (0.46) | VNN1IDH2CTSLCTSSCTSK | |
| SCHEMBL6016938 | 0.86 | GBA1 (0.42) | VNN1GBA1 | |
| SCHEMBL4829443 | 0.85 | CTSS (0.46) | VNN1IDH2CTSLCTSSCTSK | |
| SCHEMBL14293847 | 0.84 | DRD2 (0.38) | VNN1CTSLCTSSCTSK | |
| SCHEMBL4835437 | 0.84 | CTSL (0.41) | VNN1IDH2CTSLCTSSCTSK | |
| SCHEMBL4832562 | 0.84 | CTSV (0.55) | IDH2CTSLCTSSCTSKCTSV | |
| SCHEMBL14268895 | 0.83 | ACHE (0.47) | CTSSCTSK | |
| SCHEMBL5554946 | 0.83 | CCNA2 (0.39) | VNN1GALR1CDK1GBA1 | |
| SCHEMBL4838919 | 0.83 | PIM1 (0.46) | VNN1CTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7268134-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-20050113341-A1 | Medical devices employing triazine compounds and compositions thereof | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113341-A1 | Medical devices employing triazine compounds and compositions thereof | PTGIS, AREG, TGFB1 | VNN1 2533/4885GALR2 712/4885GALR1 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.